The lung cancer therapy landscape is entering a period of rapid change that should last for the next several years, starting first with the new approvals of Merck & Co. Inc.'sPD-1inhibitorKeytruda in newly diagnosed patients and with the second-line sphere opening up to Roche's PD-L1 inhibitor Tecentriq. The culmination of combination trials will cause further upheaval in the near future.
PD-1 Deep Dive: Lung Cancer Market Braced For Change
Execs speculated during third-quarter earnings calls about the impact of FDA approval for Merck's Keytruda in first-line lung cancer and looked forward to readouts of combination studies, which could soon bring another market shake-up.
More from Anticancer
More from Therapy Areas
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.